Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ceftibuten/Ledaborbactam etzadroxil - VenatoRx Pharmaceuticals

Next Previous
Drug Profile

Ceftibuten/Ledaborbactam etzadroxil - VenatoRx Pharmaceuticals

Alternative Names: BL/VNRX-7145; Ceftibuten/VNRX-7145; CTB-LED-E; CTB-LEDA; VNRX-7145

Latest Information Update: 03 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VenatoRx Pharmaceuticals
  • Developer Basilea Pharmaceutica; VenatoRx Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Amides; Amines; Antibacterials; Azabicyclo compounds; Beta-lactams; Carboxylic acids; Cephalosporins; Esters; Small molecules; Thiazoles; Urinary anti-infective agents
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Urinary tract infections
  • Phase I Bacterial infections

Most Recent Events

  • 25 Feb 2026 Basilea Pharmaceutica received grant from Biomedical Advanced Research and Development Authority for Ceftibuten/Ledaborbactam etzadroxil
  • 24 Feb 2026 Phase-II clinical trials in Urinary tract infections (PO) prior to February 2026 (Basilea Pharmaceutica pipeline, February 2026)
  • 17 Feb 2026 Basilea Pharmaceutica plans to launch Ceftibuten/ledaborbactam etzadroxil by 2030

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top